Back to Authors

Leung, John

https://orcid.org/0000-0003-4208-8955

Mayo Clinic

Tufts Medical Center

Citations 6

Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort
Hirano, Ikuo , King, Eileen, Sun, Qin , Chehade, Mirna , Abonia, J. Pablo , Bonis, Peter A, Capocelli, Kelly E., Dellon, Evan S. , Gonsalves, Nirmala , Gupta, Sandeep K. , Leung, John , Katzka, David A. , Menard‐Katcher, Paul , Khoury, Paneez , Shoda, Tetsuo, Rudman-Spergel, Amanda K., Spergel, Jonathan A., Rothenberg, Marc E., Aceves, Seema S. , Furuta, Glenn T. , investigators, CEGIR, Katzka, David, Collins, Margaret H. , Falk, Gary W. , Klion, Amy D. , Mukkada, Vincent A. , Peterson, Kathryn A. , Shoda, Tetsuo , Spergel, Jonathan A., Yang, Guang‐Yu , investigators, CEGIR

American Journal of Gastroenterology | January 26, 2022 | Volume: 117 | Issue: 3 | Pages: 413-423

10.14309/ajg.0000000000001625 Get It

INTRODUCTION: Eosinophilic gastritis (EG) is a chronic inflammatory disease of the stomach characterized by eosinophil-predominant gastric mucosal inflammation and gastrointestinal symptoms. The aim of this study was to prospectively evaluate endoscopic features in a large series of children and adults with EG to better understand the endoscopic manifestations and develop a standardized instrument for investigations. METHODS: Data were prospectively collected as part of the Consortium for Eosinophilic Gastrointestinal Disease Researchers, a national collaborative network. Endoscopic features were prospectively recorded using a system specifically developed for EG, the EG Endoscopic Reference System (EG-REFS). Correlations were made between EG-REFS and clinical and histologic features. RESULTS: Of 98 patients with EG, 65 underwent assessments using EG-REFS. The most common findings were erythema (72%), raised lesions (49%), erosions (46%), and granularity (35%); only 8% of patients with active histology (≥30 eosinophils/high-power field) exhibited no endoscopic findings. A strong correlation between EG-REFS scores and physician global assessment of endoscopy severity was demonstrated (Spearman r = 0.84, P < 0.0001). The overall score and specific components of EG-REFS were more common in the antrum than in the fundus or body. EG-REFS severity was significantly correlated with active histology, defined by a threshold of ≥30 eosinophils/high-power field ( P = 0.0002). DISCUSSION: Prospective application of EG-REFS identified gastric features with a strong correlation with physician global assessment of endoscopic activity in EG. Endoscopic features demonstrated greater severity in patients with active histology and a predilection for the gastric antrum. Further development of EG-REFS should improve its utility in clinical studies.
S1421 Safety and Efficacy of Long-Term Treatment With Lirentelimab, A Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis and/or Duodenitis
Chehade, Mirna , Leung, John , Hazan, Sabine , Vaezi, Michael F. , Bledsoe, Adam C. , Durrani, Sandy , Shaw, Camilla, Chang, Alan K. , Singh, Bhupinder , Kamboj, Amol P. , Rasmussen, Henrik , Hirano, Ikuo , Murray, Joseph A. , Peterson, Kathryn A. , Falk, Gary W. , Gonsalves, Nirmala , Genta, Robert M. , Khoury, Paneez , Klion, Amy D. , Wang, Chao , Chang, Alan, Rothenberg, Marc E. , Dellon, Evan S.

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S651-S652

10.14309/01.ajg.0000779216.88552.60 Get It

High Patient Disease Burden in a Cross‐sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases
Jensen, Elizabeth T. , Aceves, Seema S. , Bonis, Peter A, Bray, Kimberly, Book, Wendy , Chehade, Mirna , Dellon, Evan S. , Gonsalves, Nirmala , Gupta, Sandeep K. , Hirano, Ikuo , Katzka, David A. , Kyle, Shay, Mack, Denise, Kodroff, Ellyn, Leung, John , Scott, Melissa, Paliana, Ally, Sable, Kathleen, Strobel, Mary Jo, Krischer, Jeffrey P. , group, CEGIR Investigator, Collins, Margaret H. , Falk, Gary W. , Mukkada, Vincent A. , Spergel, Jonathan M. , Rothenberg, Marc E. , Abonia, J. Pablo , group, CEGIR Investigator

Journal of Pediatric Gastroenterology and Nutrition | June 15, 2020 | Volume: 71 | Issue: 4 | Pages: 524-529

10.1097/mpg.0000000000002817 Get It

ABSTRACT Objectives: Clinical features of eosinophilic esophagitis (EoE) have been well‐described in the literature, however, characterization of features experienced by patients with other eosinophilic gastrointestinal diseases (EGIDs) is lacking. Using data collected from a patient contact registry, we sought to characterize and contrast patient‐reported gastrointestinal and extragastrointestinal symptoms and comorbidities in non‐EoE EGIDs, including eosinophilic gastritis, gastroenteritis and colitis, relative to EoE. Methods: We conducted a cross‐sectional study of contact registry data collected from 2015 to 2018. Statistical comparisons were made using chi‐square (categorical measures) and the Mann‐Whitney U test (continuous measures). Multivariable analyses were used to evaluate associations between treatment and feelings of isolation. Results: Of the 715 reporting an EGID diagnosis (n = 525 EoE; n = 190 non‐EoE EGID), a higher proportion of those with a non‐EoE EGID reported more frequent specific and nonspecific gastrointestinal symptoms, including nausea, abdominal pain, diarrhea, constipation, and bloating ( P < 0.01 for all). Participants with a non‐EoE EGID were more likely to report higher frequency of fatigue, isolation, and deep muscle or joint pain ( P < 0.01 for all). Specific food elimination and elemental formula treatments were associated with increased odds of more frequent (at least weekly) feelings of isolation for participants with EoE (adjusted odds rtaio [aOR]: 2.4; 95% confidence interval [CI]: 1.5‐‐4.1 for specific food elimination and adjusted OR: 1.9; 95% CI: 1.2‐‐3.3 for elemental formula). Conclusions: Significant differences exist in the symptoms and comorbidities experienced between those with EoE versus non‐EoE EGIDs. Additional investigation is needed to elucidate the factors that may contribute to the high disease burden of these poorly understood conditions.
1244 Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Enteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia: A New Diagnostic Entity?
Chehade, Mirna , Khoury, Paneez , Leung, John , Bledsoe, Adam C. , Shaw, Camilla, Rasmussen, Henrik , Singh, Bhupinder , Chang, Alan T., Youngblood, Bradford A. , Kamboj, Amol P. , Hirano, Ikuo , Murray, Joseph A. , Dellon, Evan S. , Peterson, Kathryn A. , Falk, Gary W. , Genta, Robert M. , Gonsalves, Nirmala , Rothenberg, Marc E.

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S693-S694

10.14309/01.ajg.0000594504.91508.61 Get It

INTRODUCTION: Eosinophilic gastrointestinal diseases (EGIDs) are a set of inflammatory diseases subclassified according to the site(s) of abnormal accumulation of eosinophils (eos) in the gastrointestinal (GI) tract such as eosinophilic esophagitis (EoE), gastroenteritis (EGE), and colitis. These conditions often decrease quality of life due to debilitating symptoms. While the pathogenesis of EGIDs is primarily thought to be driven by eos, there is increasing evidence for the involvement of mast cells (MCs). AIM: To characterize symptomatic patients (pts) with suspected EG/EGE who did not meet histopathologic entry criteria for mucosal eosinophilia for a Phase 2 randomized, double-blind, placebo-controlled study of AK002, an anti-Siglec-8 antibody. METHODS: To undergo screening endoscopy for this study, pts were required to report an average symptom score ≥3 (0 to 10 scale) for abdominal pain, nausea, and/or diarrhea on a daily patient-reported outcome questionnaire for ≥2 weeks and have no other known cause for GI symptoms. During the screening endoscopy, biopsies were systematically obtained from the stomach and duodenum, and read by a single pathologist. Eos counts (eos/hpf; hpf area = 0.237 mm 2 ) were assessed on H&E slides. To quantify MCs, immunohistochemistry for tryptase was performed. We quantified eos and MCs in the stomach and duodenum. Histopathologic entry criteria for the randomized study was ≥30 eos/hpf in 5 hpfs in the stomach (EG) and/or ≥30 eos/hpf in 3 hpfs in the duodenum (EGE). A literature review was conducted to determine normal MC counts in the GI tract. RESULTS: Eighty-eight pts underwent screening endoscopy based upon suspected EG/EGE and active symptoms, and 72 pts met histopathologic eos criteria. All pts whose eos did not meet entry criteria (n = 16) were found to have elevated MC counts (Figure 1; reported normal range = 12-19 MCs/hpf). In these pts, the mean gastric eos count was 6 eos/hpf in 5 hpfs and mean duodenal eos count was 15 eos/hpf in 3 hpfs. In contrast, these pts exhibited a mean gastric MC count of 47 MC/hpf in 5 hpfs and a mean duodenal MC count of 49 MC/hpf in 3 hpfs. Almost all symptomatic pts screened (87/88; 99%) had elevated MC counts. CONCLUSION: Data from this large randomized EG/EGE study showed that symptomatic pts with suspected EG/EGE had increased mucosal MCs with or without mucosal eosinophilia. These data suggest that MCs may play a role in pts with suspected EG/EGE and raise the possibility of a unique clinical presentation driven by MCs.